Daily Derm Times: March 14, 2025

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Blending Clinical Practice and Social Media with Chris Tomassian, MD

By staying authentic and leveraging real patient experiences, Tomassian ensures his content remains valuable and trustworthy.

Hyperpigmentation Advice on TikTok: Reliable or Risky?

A study analyzed TikTok’s top 50 videos on hyperpigmentation in skin of color, revealing a discrepancy between engagement and medical accuracy.

Key Insights from Novartis at AAD and AAAAI: Flexibility and Personalization in Dermatology Treatment

Novartis highlighted key findings at AAD and AAAAI, showcasing Cosentyx's flexible dosing for hidradenitis suppurativa and remibrutinib’s efficacy for chronic spontaneous urticaria.

How Do Diet and Blood Zonulin Levels Impact Acne Severity?

Red meat, chocolate, milk, and foods with a high glycemic index may impact the presence of acne in patients.

Amlitelimab Demonstrates Durable Response in Atopic Dermatitis

Karl Yen of Sanofi discussed the role of amlitelimab in AD following sustained results and a promising safety profile presented in data at AAD.

Home Phototherapy Proves Effective and Preferred in LITE Study for Psoriasis Treatment

The LITE study found home-based narrowband UV-B phototherapy is as effective as office-based treatment for psoriasis, with higher adherence and lower costs.

Improving Social Determinants of Health Essential for Better AD Outcomes in Pediatric Patients of Color

Amid limited access to pediatric dermatologists nationwide, pediatric patients of color with atopic dermatitis are particularly affected by social determinants of health, further impacting their outcomes.

Closing Out AAD With Dermatology Times’ Editor in Chief

Christopher Bunick, MD, PhD, shares concluding remarks with colleagues at AAD 2025.

AAD 2025: Conference Recap

Catch up on all coverage from the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida, March 7-11.